Britain on Thursday approved the use of Merck’s antiviral pill to treat patients suffering from mild to moderate coronavirus infections, the Medicines and Healthcare products Regulatory Agency (MHRA) announced.
“Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for Covid-19,” AFP quoted health minister Sajid Javid as saying.
AP, on its part, reports that the pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe diseases, such as obesity or heart disease.
The drug, known as molnupiravir, is intended to be taken twice a day for five days by people at home with mild to moderate COVID-19.
An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems.
It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
Molnupiravir is also pending review at regulators in the U.S., the European Union and elsewhere.
The U.S. Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinize the pill’s safety and effectiveness in late November.
Initial supplies will be limited.
Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.
In October, U.K. officials announced they secured 480,000 courses of molnupiravir and expected thousands of vulnerable Britons to have access to the treatment this winter via a national study.
“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” he said in a statement, referring to the U.K.’s National Health Service.
Doctors said the treatment would be particularly significant for people who do not respond well to vaccination.
Merck and its partner Ridgeback Biotherapeutic have requested clearance for the drug with regulators around the world to treat adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization.
That’s roughly the same group targeted for treatment with infused COVID-19 antibody drugs, the standard of care in many countries for patients who don’t yet require hospitalization.
Merck announced preliminary results last month showing its drug cut hospitalizations and deaths by half among patients with early COVID-19 symptoms.
The results have not yet been peer-reviewed or published in a scientific journal.
The company also did not disclose details on molnupiravir’s side effects, except to say that rates of those problems were similar between people who got the drug and those who received dummy pills.
The drug targets an enzyme the coronavirus uses to reproduce itself, inserting errors into its genetic code that slows its ability to spread and take over human cells.
That genetic activity has led some independent experts to question whether the drug could potentially cause mutations leading to birth defects or tumours.
